FDA Grants Full Approval of KBroVet Epilepsy Drug for Dogs

Approval Granted After Expanded Conditional Pathway

The U.S. Food and Drug Administration has granted full approval to KBroVet® (potassium bromide chewable tablets) for the control of seizures in dogs diagnosed with idiopathic epilepsy, a chronic seizure disorder with no identifiable underlying cause. Idiopathic epilepsy affects an estimated 5% of the canine population and can be life-threatening if not properly managed.

KBroVet is administered orally daily and is available by prescription only, reflecting the need for veterinary diagnosis, individualized dosing, and ongoing clinical monitoring.

Veterinary Oversight and Safety Considerations

Because potassium bromide has a narrow safety margin, veterinarians play a critical role in monitoring treatment. Dog owners are advised to work closely with their veterinary care team to observe clinical signs and help prevent bromide intoxication, a condition that can occur when bromide levels become excessive in the nervous system.

Potential signs of severe bromide toxicity include depression or behavioral changes, poor coordination or weakness, partial loss of hind limb motor function, dilated pupils, or stupor or coma.

Dietary consistency is also essential. Abrupt changes in diet, particularly sodium intake, can interfere with seizure control or increase safety risks in dogs receiving potassium bromide therapy.

Regulatory Background: Expanded Conditional Approval

KBroVet was conditionally approved in January 2021, becoming the first animal drug authorized under the FDA’s expanded conditional approval pathway for certain new animal drugs not classified as Minor Use/Minor Species (MUMS).

This regulatory pathway is designed for serious or life-threatening conditions, unmet veterinary medical needs, and situations where demonstrating effectiveness requires complex or prolonged studies.

Under expanded conditional approval, a product may be marketed for one year at a time, with up to four annual renewals, provided the sponsor demonstrates active progress toward generating substantial evidence of effectiveness.

If full approval is not achieved within five years, the product may no longer be marketed.

Transition to Full Approval

After four annual renewals, the drug’s sponsor, Pegasus Laboratories, Inc., submitted the required effectiveness data to support full FDA approval. With this action, KBroVet now meets the FDA’s standard evidentiary requirements for both safety and effectiveness.

Why This Matters

This approval highlights the FDA’s evolving regulatory tools for addressing unmet veterinary health needs, the importance of post-approval data generation and regulatory accountability, and a growing recognition of chronic neurologic conditions in companion animals.

For veterinarians, manufacturers, and animal health stakeholders, KBroVet’s regulatory journey provides a clear example of how expanded conditional approval can bridge urgent clinical needs while maintaining long-term regulatory rigor.

Read the FDA announcement here.